XML 30 R18.htm IDEA: XBRL DOCUMENT

Equity Incentive Plans (Tables)

9 Months Ended

Sep. 30, 2017

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

A summary of the status of the Company’s option plans as of September 30, 2017 and changes during the period then ended is presented below:

	Nine months ended September 30, 2017
	Unaudited
	Number of options			Weighted average exercise price
Outstanding at beginning of year		11,377,354		$	9.76
Granted		5,117,088			9.96
Exercised		(1,370,810	)		2.31
Forfeited and cancelled		(310,693	)		12.39
Outstanding as of September 30, 2017		14,812,939			10.46

Exercisable options		6,119,710			8.17

Vested and expected to vest		14,812,939		$	10.46

Schedule of RSU's

A summary of the status of the Company’s RSUs as of September 30, 2017 and changes during the period then ended is presented below:

	Nine months ended September 30, 2017
	Unaudited
	Number of RSUs			Weighted average grant date fair value price
Unvested at beginning of year		-		$	-
Granted		1,661,619			9.64
Vested		-			-
Forfeited and cancelled		(10,400	)		7.15
Unvested as of September 30, 2017		1,651,219		$	9.66

Schedule of Fair Value Assumptions Used Only for Equity Based Awards Estimated Using Black-Scholes Option Pricing Model

The fair value of all equity-based awards was estimated using the Black-Scholes option-pricing model with the following underlying assumptions, excluding market condition awards for which fair value was estimated using the Monte Carlo option-pricing model:

	Nine months ended September 30,			Year ended December 31,
	2017	2016		2016
	Unaudited			Audited
Stock Option Plans
Expected term (years)	5.5-6.25	6.25		6.25
Expected volatility	56.74%-59.45%	59.80%-61.65%		58.40%-61.70%
Risk-free interest rate	1.97%-2.23%	1.23%-1.88%		1.23%-1.88%
Dividend yield	0.00%	0.00%		0.00%
ESPP
Expected term (years)	0.50		0.42	0.42
Expected volatility	76.37%-82.00%	70.45%		70.45%
Risk-free interest rate	0.62%-1.13%	0.40%		0.40%
Dividend yield	0.00%	0.00%		0.00%

Schedule of Non-cash Share-based Compensation Expense Related to Company's Equity-Based Awards

The total non-cash share-based compensation expense related to all of the Company’s equity-based awards recognized for the three and nine months ended September 30, 2017 and 2016 and the year ended December 31, 2016 was:

	Three months ended September 30,				Nine months ended September 30,				Year ended December 31,
	2017		2016		2017		2016		2016
	Unaudited				Unaudited				Audited
Cost of revenues	$	79	$	160	$	353	$	471	$	623
Research, development and clinical trials		972		776		2,645		2,378		3,155
Sales and marketing		1,874		1,249		4,264		3,888		5,111
General and administrative		5,704		3,441		13,498		9,982		12,552
Total share-based compensation expense	$	8,629	$	5,626	$	20,760	$	16,719	$	21,441